Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients
Ma et al., AACR Annual Meeting 2022 (In Vitro)
Ma et al., Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild,.., AACR Annual Meeting 2022 (In Vitro)
Review of the mechanisms of action of proxalutamide for COVID-19, and In Vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC50 of 69, 48 and 39nM. Only the abstract is currently available.
Ma et al., 8 Apr 2022, peer-reviewed, 12 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.